{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:04:48Z","timestamp":1781625888750,"version":"3.54.5"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ecl.2026.01.002","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:00:34Z","timestamp":1772100034000},"page":"299-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors"],"prefix":"10.1016","volume":"55","author":[{"given":"Samantha E.","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Skefos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Vagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.ecl.2026.01.002_bib1","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.20.03661","article-title":"Therapeutic implications of germline testing in patients with advanced cancers","volume":"39","author":"Stadler","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ecl.2026.01.002_bib2","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac019","article-title":"Surveillance improves outcomes for carriers of SDHB pathogenic variants: a multi-center study","author":"Davidoff","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13696998.2022.2152233","article-title":"A review of the cost-effectiveness of genetic testing for germline variants in familial cancer","volume":"26","author":"Teppala","year":"2023","journal-title":"J Med Econ"},{"key":"10.1016\/j.ecl.2026.01.002_bib4","unstructured":"Gemmell APR, P.; Fenter, R.; Luong, M.; et al Assessing criteria for germline evaluation based on somatic genetic test results. 2024."},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41525-023-00374-9","article-title":"Clinically significant germline pathogenic variants are missed by tumor genomic sequencing","volume":"8","author":"Stout","year":"2023","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.ecl.2026.01.002_bib6","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac014","article-title":"Universal germline panel testing for individuals with pheochromocytoma and paraganglioma produces high diagnostic yield","author":"Horton","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.002_bib7","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41436-021-01262-2","article-title":"Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer","volume":"23","author":"Hamilton","year":"2021","journal-title":"Genet Med"},{"issue":"S 01","key":"10.1016\/j.ecl.2026.01.002_bib8","article-title":"A cost-effectiveness review of genetic testing of paragangliomas","volume":"84","author":"Abbasi","year":"2023","journal-title":"J Neurol Surg B Skull Base"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ygyno.2022.08.011","article-title":"Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective","volume":"167","author":"Bokkers","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.002_bib10","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/gim.2017.231","article-title":"Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers","volume":"20","author":"Tuffaha","year":"2018","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.002_bib11","doi-asserted-by":"crossref","first-page":"E476","DOI":"10.1210\/jc.2011-1982","article-title":"TP53 germline mutations in adult patients with adrenocortical carcinoma","volume":"97","author":"Herrmann","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib12","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1210\/jc.2012-2198","article-title":"Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma","volume":"98","author":"Raymond","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.ecl.2026.01.002_bib13","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1073\/pnas.161479898","article-title":"An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma","volume":"98","author":"Ribeiro","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.002_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrendo.2017.166","article-title":"Expert consensus document: clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement","volume":"14","author":"Brioude","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"23","key":"10.1016\/j.ecl.2026.01.002_bib15","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-24-2100","article-title":"Update on surveillance for Wilms tumor and hepatoblastoma in Beckwith-Wiedemann Syndrome and other predisposition syndromes","volume":"30","author":"Kalish","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ecl.2026.01.002_bib16","series-title":"GeneReviews((R))","article-title":"Beckwith-Wiedemann syndrome","author":"Shuman","year":"1993"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.002_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1210\/clinem\/dgaa833","article-title":"Characteristics of adrenocortical carcinoma associated with Lynch syndrome","volume":"106","author":"Domenech","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.ecl.2026.01.002_bib18","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a lynch syndrome-associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.002_bib20","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2013.52.6863","article-title":"Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children\u2019s oncology group study","volume":"33","author":"Wasserman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.002_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.21151","article-title":"Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect","volume":"31","author":"Garritano","year":"2010","journal-title":"Hum Mutat"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.002_bib22","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001883","article-title":"Tumor suppressive functions of p53","volume":"1","author":"Zilfou","year":"2009","journal-title":"Cold Spring Harbor Perspect Biol"},{"issue":"18","key":"10.1016\/j.ecl.2026.01.002_bib23","first-page":"5358","article-title":"A cancer family syndrome in twenty-four kindreds","volume":"48","author":"Li","year":"1988","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ecl.2026.01.002_bib24","first-page":"1932","article-title":"P53 germline mutations in childhood cancers and cancer risk for carrier individuals","volume":"82","author":"Chompret","year":"2000","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.ecl.2026.01.002_bib25","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1158\/1078-0432.CCR-24-3301","article-title":"Update on cancer screening recommendations for individuals with Li-Fraumeni Syndrome","volume":"31","author":"Achatz","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ecl.2026.01.002_bib26","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic\/familial high-risk assessment: colorectal, endometrial, and gastric. 2025."},{"key":"10.1016\/j.ecl.2026.01.002_bib27","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac105","article-title":"Systematic review: incidence of pheochromocytoma and paraganglioma over 70 years","author":"Al Subhi","year":"2022","journal-title":"J Endoc Soc"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.002_bib28","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1245\/s10434-013-2942-5","article-title":"Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing","volume":"20","author":"Fishbein","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.002_bib29","doi-asserted-by":"crossref","first-page":"E1352","DOI":"10.1210\/jc.2013-4375","article-title":"Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma","volume":"99","author":"Welander","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/ERC-13-0415","article-title":"Long-term prognosis of patients with pediatric pheochromocytoma","volume":"21","author":"Bausch","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.002_bib31","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ecl.2026.01.002_bib32","series-title":"GeneReviews((R))","article-title":"FH tumor predisposition syndrome","author":"Kamihara","year":"1993"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.002_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101958","article-title":"Recent progress in the pathologic classification of pheochromocytomas and paragangliomas","volume":"38","author":"Mete","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.002_bib34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00441-018-2795-0","article-title":"Chromaffin cell biology: inferences from the cancer genome Atlas","volume":"372","author":"Fishbein","year":"2018","journal-title":"Cell Tissue Res"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.002_bib35","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.tem.2017.08.001","article-title":"New insights into the nuclear imaging phenotypes of cluster 1 pheochromocytoma and paraganglioma","volume":"28","author":"Ta\u00efeb","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.01.002_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2478\/enr-2018-0006","article-title":"Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs)","volume":"52","author":"Khatami","year":"2018","journal-title":"Endocr Regul"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.002_bib37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jmedgenet-2018-105427","article-title":"Bayesian approach to determining penetrance of pathogenic SDH variants","volume":"55","author":"Benn","year":"2018","journal-title":"J Med Genet"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.002_bib38","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1210\/jc.2017-01762","article-title":"Clinical aspects of SDHA-related pheochromocytoma and paraganglioma: a nationwide study","volume":"103","author":"Van Der Tuin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.002_bib39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1210\/js.2018-00120","article-title":"Pathogenicity and penetrance of germline SDHA variants in pheochromocytoma and Paraganglioma (PPGL)","volume":"2","author":"Maniam","year":"2018","journal-title":"J Endocr Soc"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.002_bib40","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamaoncol.2017.0223","article-title":"Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention","volume":"3","author":"Bausch","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ecl.2026.01.002_bib41","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0111","article-title":"SDHA related phaeochromocytoma and paraganglioma: review and clinical management","author":"Kaplan","year":"2024","journal-title":"Endocr Relat Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ecl.2026.01.002_bib42","doi-asserted-by":"crossref","first-page":"10610","DOI":"10.1200\/JCO.2025.43.16_suppl.10610","article-title":"Characterization of hereditary tumor risk in individuals with SDHA germline variants","volume":"43","author":"Ellis","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib43","article-title":"Hereditary and clinical insights into paraganglioma and pheochromocytoma","volume":"4","author":"Mauer Hall","year":"2024","journal-title":"Endocr Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/cge.13055","article-title":"The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers","volume":"93","author":"Rijken","year":"2018","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.002_bib45","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype\u2013phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD","volume":"55","author":"Andrews","year":"2018","journal-title":"J Med Genet"},{"issue":"8","key":"10.1016\/j.ecl.2026.01.002_bib46","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00432-017-2397-3","article-title":"SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations","volume":"143","author":"Jochmanova","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/humu.21136","article-title":"Tumor risks and genotype\u2013phenotype\u2013proteotype analysis in 358 patients with germline mutations in SDHB and SDHD","volume":"31","author":"Ricketts","year":"2010","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00431-015-2614-5","article-title":"Sporadic paraganglioma caused by de novo SDHB mutations in a 6-year-old girl","volume":"175","author":"Imamura","year":"2016","journal-title":"Eur J Pediatr"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.002_bib49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.002_bib50","doi-asserted-by":"crossref","first-page":"E489","DOI":"10.1210\/jc.2013-3486","article-title":"Phenotypic variability and risk of malignancy inSDHC-Linked paragangliomas: lessons from three unrelated cases with an identical germline mutation (p.Arg133\u2217)","volume":"99","author":"Bickmann","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.01.002_bib51","article-title":"SDHC phaeochromocytoma and paraganglioma: a UK-wide case series","author":"Williams","year":"2021","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.002_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70669","article-title":"A review of genomic testing and SDH- deficiency in gastrointestinal stromal tumors: getting to the GIST","volume":"14","author":"Florou","year":"2025","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.002_bib53","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41431-018-0116-4","article-title":"Clinical progression and metachronous paragangliomas in a large cohort of SDHD germline variant carriers","volume":"26","author":"Heesterman","year":"2018","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.002_bib54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jmedgenet-2016-104297","article-title":"Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma","volume":"54","author":"Burnichon","year":"2017","journal-title":"J Med Genet"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.002_bib55","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1210\/js.2018-00353","article-title":"A family with a carotid body paraganglioma and thyroid neoplasias with a new SDHAF2 germline variant","volume":"3","author":"Wolf","year":"2019","journal-title":"J Endocr Soc"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.002_bib56","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(10)70007-3","article-title":"SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma","volume":"11","author":"Bayley","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ecl.2026.01.002_bib57","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaf149","article-title":"New insights into the clinical characterisation of SDHAF2-related familial paraganglioma syndrome","author":"Fernandez-Pombo","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.01.002_bib58","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-4354","article-title":"Update on tumor surveillance for children with hereditary pheochromocytoma\/paraganglioma syndromes","author":"Rednam","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ecl.2026.01.002_bib59","article-title":"Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients","author":"Lussey-Lepoutre","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.ecl.2026.01.002_bib60","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement","author":"Ta\u00efeb","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ecl.2026.01.002_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","author":"Ta\u00efeb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ecl.2026.01.002_bib62","doi-asserted-by":"crossref","DOI":"10.1530\/EO-23-0043","article-title":"SDHA secondary findings in germline testing: counseling and surveillance considerations","author":"Skefos","year":"2024","journal-title":"Endocrine Oncol"},{"key":"10.1016\/j.ecl.2026.01.002_bib63","article-title":"UK recommendations for SDHA germline genetic testing and surveillance in clinical practice","author":"Hanson","year":"2022","journal-title":"J Med Genet"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.002_bib64","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1530\/EC-21-0455","article-title":"Metastatic cluster 2-related pheochromocytoma\/paraganglioma: a single-center experience and systematic review","volume":"10","author":"Kumar","year":"2021","journal-title":"Endocr Connect"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.002_bib65","doi-asserted-by":"crossref","first-page":"E805","DOI":"10.1210\/jc.2011-3360","article-title":"TMEM127 screening in a large cohort of patients with pheochromocytoma and\/or paraganglioma","volume":"97","author":"Abermil","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.01.002_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1442691","article-title":"Genotype and clinical phenotype characteristics of MAX germline mutation-associated pheochromocytoma\/paraganglioma syndrome","volume":"15","author":"Lian","year":"2024","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib67","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1210\/clinem\/dgaa741","article-title":"Genotype-phenotype features of germline variants of the TMEM127 pheochromocytoma susceptibility gene: a 10-Year update","volume":"106","author":"Armaiz-Pena","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.01.002_bib68","article-title":"Genotype-phenotype correlations and clinical outcomes in 155 cases of pheochromocytoma and paraganglioma","author":"Wang","year":"2022","journal-title":"World J Surg"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.002_bib69","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13023-025-03554-1","article-title":"The mutational landscape of ARMC5 in primary bilateral macronodular adrenal hyperplasia: an update","volume":"20","author":"Bouys","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1530\/EJE-21-1032","article-title":"Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene ARMC5 in 352 unselected patients","volume":"187","author":"Bouys","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.002_bib72","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12020-021-02645-w","article-title":"Update on primary bilateral macronodular adrenal hyperplasia (PBMAH)","volume":"71","author":"Bouys","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.ecl.2026.01.002_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1685220","article-title":"Germline targeted next-generation sequencing in patients with adrenal incidentalomas","volume":"16","author":"Messina","year":"2025","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.002_bib74","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.002_bib75","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1210\/clinem\/dgab866","article-title":"Pathological and genetic stratification for management of adrenocortical carcinoma","volume":"107","author":"Clay","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.01.002_bib76","first-page":"16","article-title":"Diagnosis and treatment of paragangliomas and pheochromocytomas: a survey from the Italian Association for Neuroendocrine Tumors. Original Research","author":"Pietroluongo","year":"2025","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.002_bib77","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The north American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.ecl.2026.01.002_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/cen.15248","article-title":"Genetic testing referral rates for pheochromocytoma and paraganglioma in an academic tertiary centre","author":"Ruhle","year":"2025","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ecl.2026.01.002_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107600","article-title":"Implementation of point-of-care genetic testing for head and neck paragangliomas: early experience and future directions","volume":"168","author":"Beiriger","year":"2025","journal-title":"Oral Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.002_bib80","article-title":"Succinate dehydrogenase pathogenic variants among older adults with head and neck paragangliomas","volume":"10","author":"Bellamkonda","year":"2025","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.002_bib81","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:51:34Z","timestamp":1781621494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0889852926000022"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.01.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}